Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2016, Article ID 6093783, 16 pages
http://dx.doi.org/10.1155/2016/6093783
Research Article

Myricitrin Protects against Doxorubicin-Induced Cardiotoxicity by Counteracting Oxidative Stress and Inhibiting Mitochondrial Apoptosis via ERK/P53 Pathway

1Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Chaoyang District, Beijing 100029, China
2Key Laboratory of Bioactive Substances and Resources Utilization of Chinese Herbal Medicine, Ministry of Education, Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences and Peking Union Medical College, Haidian District, Beijing 100193, China

Received 3 March 2016; Revised 8 May 2016; Accepted 5 June 2016

Academic Editor: G. K. Jayaprakasha

Copyright © 2016 Jing Sun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. X. Tan, D.-B. Wang, X. Lu et al., “Doxorubicin induces apoptosis in H9c2 cardiomyocytes: role of overexpressed eukaryotic translation initiation factor 5A,” Biological and Pharmaceutical Bulletin, vol. 33, no. 10, pp. 1666–1672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Takemura and H. Fujiwara, “Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management,” Progress in Cardiovascular Diseases, vol. 49, no. 5, pp. 330–352, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Chen, X. Peng, L. Pentassuglia, C. C. Lim, and D. B. Sawyer, “Molecular and cellular mechanisms of anthracycline cardiotoxicity,” Cardiovascular Toxicology, vol. 7, no. 2, pp. 114–121, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. H. Lou, K. Kaur, A. K. Sharma, and P. K. Singal, “Adriamycin-induced oxidative stress, activation of MAP kinases and apoptosis in isolated cardiomyocytes,” Pathophysiology, vol. 13, no. 2, pp. 103–109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. A. R. L. Ludke, A. A.-R. S. Al-Shudiefat, S. Dhingra, D. S. Jassal, and P. K. Singal, “A concise description of cardioprotective strategies in doxorubicin-induced cardiotoxicity,” Canadian Journal of Physiology and Pharmacology, vol. 87, no. 10, pp. 756–763, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. J. H. Doroshow, G. Y. Locker, and C. E. Myers, “Enzymatic defenses of the mouse heart against reactive oxygen metabolites. Alterations produced by doxorubicin,” The Journal of Clinical Investigation, vol. 65, no. 1, pp. 128–135, 1980. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Kalyanaraman, J. Joseph, S. Kalivendi, S. Wang, E. Konorev, and S. Kotamraju, “Doxorubicin-induced apoptosis: Implications in cardiotoxicity,” Molecular and Cellular Biochemistry, vol. 234-235, pp. 119–124, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. W. Zhang, J. Shi, Y. J. Li, and L. Wei, “Cardiomyocyte death in doxorubicin-induced cardiotoxicity,” Archivum Immunologiae et Therapia Experimentalis, vol. 57, no. 6, pp. 435–445, 2009. View at Publisher · View at Google Scholar
  9. S. W. Ryter, P. K. Hong, A. Hoetzel et al., “Mechanisms of cell death in oxidative stress,” Antioxidants and Redox Signaling, vol. 9, no. 1, pp. 49–89, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Xiao, G.-B. Sun, B. Sun et al., “Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro,” Toxicology, vol. 292, no. 1, pp. 53–62, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Liu, W. Mao, B. Ding, and C.-S. Liang, “ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 295, no. 5, pp. H1956–H1965, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. J. Huang, J. Yang, B. Maity, D. Mayuzumi, and R. A. Fisher, “Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism,” Cancer Research, vol. 71, no. 20, pp. 6310–6319, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. V. A. Sardão, P. J. Oliveira, J. Holy, C. R. Oliveira, and K. B. Wallace, “Doxorubicin-induced mitochondrial dysfunction is secondary to nuclear p53 activation in H9c2 cardiomyoblasts,” Cancer Chemotherapy and Pharmacology, vol. 64, no. 4, pp. 811–827, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Berthiaume and K. B. Wallace, “Adriamycin-induced oxidative mitochondrial cardiotoxicity,” Cell Biology and Toxicology, vol. 23, no. 1, pp. 15–25, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. B. D. Paul, G. S. Rao, and G. J. Kapadia, “Isolation of myricadiol, myricitrin, taraxerol, and taraxerone from Myrica cerifera L. root bark,” Journal of Pharmaceutical Sciences, vol. 63, no. 6, pp. 958–959, 1974. View at Publisher · View at Google Scholar · View at Scopus
  16. F. C. Meotti, R. Senthilmohan, D. T. Harwood, F. C. Missau, M. G. Pizzolatti, and A. J. Kettle, “Myricitrin as a substrate and inhibitor of myeloperoxidase: implications for the pharmacological effects of flavonoids,” Free Radical Biology and Medicine, vol. 44, no. 1, pp. 109–120, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Bao, Y. Cai, M. Sun, G. Wang, and H. Corke, “Anthocyanins, flavonols, and free radical scavenging activity of Chinese bayberry (Myrica rubra) extracts and their color properties and stability,” Journal of Agricultural and Food Chemistry, vol. 53, no. 6, pp. 2327–2332, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Shimosaki, Y. Tsurunaga, H. Itamura, and M. Nakamura, “Anti-allergic effect of the flavonoid myricitrin from Myrica rubra leaf extracts in vitro and in vivo,” Natural Product Research, vol. 25, no. 4, pp. 374–380, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. F. C. Meotti, R. Fachinetto, L. C. Maffi et al., “Antinociceptive action of myricitrin: involvement of the K+ and Ca2+ channels,” European Journal of Pharmacology, vol. 567, no. 3, pp. 198–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. S. P. Fernandez, M. Nguyen, T. T. Yow et al., “The flavonoid glycosides, myricitrin, gossypin and naringin exert anxiolytic action in mice,” Neurochemical Research, vol. 34, no. 10, pp. 1867–1875, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. G.-B. Sun, M. Qin, J.-X. Ye et al., “Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE −/− mice,” Toxicology and Applied Pharmacology, vol. 271, no. 1, pp. 114–126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Qin, Y. Luo, X.-B. Meng et al., “Myricitrin attenuates endothelial cell apoptosis to prevent atherosclerosis: an insight into PI3K/Akt activation and STAT3 signaling pathways,” Vascular Pharmacology, vol. 70, pp. 23–34, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. B. D. Sahu, J. M. Kumar, M. Kuncha, R. M. Borkar, R. Srinivas, and R. Sistla, “Baicalein alleviates doxorubicin-induced cardiotoxicity via suppression of myocardial oxidative stress and apoptosis in mice,” Life Sciences, vol. 144, pp. 8–18, 2016. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Vlad, C. Şerboiu, A. T. Ispas, I. Giuvărăşteanu, E. Ungureanu, and N. Ionescu, “Electron microscopy of the morphological changes in rat viscera during experimental hyperthermic shock,” Journal of Medicine and Life, vol. 6, no. 1, pp. 55–60, 2013. View at Google Scholar · View at Scopus
  25. X. Sun, G.-B. Sun, M. Wang, J. Xiao, and X.-B. Sun, “Protective effects of cynaroside against H2O2-induced apoptosis in H9c2 cardiomyoblasts,” Journal of Cellular Biochemistry, vol. 112, no. 8, pp. 2019–2029, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Sun, G. Sun, X. Meng et al., “Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro,” PLoS ONE, vol. 8, no. 5, Article ID e64526, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. F. Bernuzzi, S. Recalcati, A. Alberghini, and G. Cairo, “Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation,” Chemico-Biological Interactions, vol. 177, no. 1, pp. 12–20, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. Q. Guo, J. Guo, R. Yang et al., “Cyclovirobuxine D attenuates doxorubicin-induced cardiomyopathy by suppression of oxidative damage and mitochondrial biogenesis impairment,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 151972, 11 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. S. J. Riedl and Y. Shi, “Molecular mechanisms of caspase regulation during apoptosis,” Nature Reviews Molecular Cell Biology, vol. 5, no. 11, pp. 897–907, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. S. C. Armstrong, “Anti-oxidants and apoptosis: attenuation of doxorubicin induced cardiomyopathy by carvedilol,” Journal of Molecular and Cellular Cardiology, vol. 37, no. 4, pp. 817–821, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. M. T. Hemann and S. W. Lowe, “The p53-Bcl-2 connection,” Cell Death and Differentiation, vol. 13, no. 8, pp. 1256–1259, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. K. Jahnukainen, T. Jahnukainen, T. T. Salmi, K. Svechniko, S. Eksborg, and O. Söder, “Amifostine protects against early but not late toxic effects of doxorubicin in infant rats,” Cancer Research, vol. 61, no. 17, pp. 6423–6427, 2001. View at Google Scholar · View at Scopus
  33. J. Goodman and P. Hochstein, “Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin,” Biochemical and Biophysical Research Communications, vol. 77, no. 2, pp. 797–803, 1977. View at Publisher · View at Google Scholar · View at Scopus
  34. T.-J. Liu, Y.-C. Yeh, C.-T. Ting et al., “Ginkgo biloba extract 761 reduces doxorubicin-induced apoptotic damage in rat hearts and neonatal cardiomyocytes,” Cardiovascular Research, vol. 80, no. 2, pp. 227–235, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. Q. Dong, L. Chen, Q. Lu et al., “Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression,” British Journal of Pharmacology, vol. 171, no. 19, pp. 4440–4454, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. Y.-F. Xin, L.-L. Wan, J.-L. Peng, and C. Guo, “Alleviation of the acute doxorubicin-induced cardiotoxicity by Lycium barbarum polysaccharides through the suppression of oxidative stress,” Food and Chemical Toxicology, vol. 49, no. 1, pp. 259–264, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Bialik, V. L. Cryns, A. Drincic et al., “The mitochondrial apoptotic pathway is activated by serum and glucose deprivation in cardiac myocytes,” Circulation Research, vol. 85, no. 5, pp. 403–414, 1999. View at Publisher · View at Google Scholar · View at Scopus
  38. X. Liu, C. C. Chua, J. Gao et al., “Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 286, no. 3, pp. H933–H939, 2004. View at Google Scholar
  39. O. J. Arola, A. Saraste, K. Pulkki, M. Kallajoki, M. Parvinen, and L.-M. Voipio-Pulkki, “Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis,” Cancer Research, vol. 60, no. 7, pp. 1789–1792, 2000. View at Google Scholar · View at Scopus
  40. M. A. Sussman, “Mitochondrial integrity: preservation through Akt/Pim-1 kinase signaling in the cardiomyocyte,” Expert Review of Cardiovascular Therapy, vol. 7, no. 8, pp. 929–938, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. P. Shan, J. Pu, A. Yuan et al., “RXR agonists inhibit oxidative stress-induced apoptosis in H9c2 rat ventricular cells,” Biochemical and Biophysical Research Communications, vol. 375, no. 4, pp. 628–633, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. L. Circu and T. Y. Aw, “Reactive oxygen species, cellular redox systems, and apoptosis,” Free Radical Biology and Medicine, vol. 48, no. 6, pp. 749–762, 2010. View at Publisher · View at Google Scholar · View at Scopus
  43. A. G. Porter and R. U. Jänicke, “Emerging roles of caspase-3 in apoptosis,” Cell Death and Differentiation, vol. 6, no. 2, pp. 99–104, 1999. View at Publisher · View at Google Scholar · View at Scopus
  44. Y.-C. Yeh, T.-J. Liu, L.-C. Wang et al., “A standardized extract of Ginkgo biloba suppresses doxorubicin-induced oxidative stress and p53-mediated mitochondrial apoptosis in rat testes,” British Journal of Pharmacology, vol. 156, no. 1, pp. 48–61, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. K. M. Regula and L. A. Kirshenbaum, “p53 activates the mitochondrial death pathway and apoptosis of ventricular myocytes independent of de novo gene transcription,” Journal of Molecular and Cellular Cardiology, vol. 33, no. 8, pp. 1435–1445, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Shih, H.-Y. Lin, F. B. Davis, and P. J. Davis, “Thyroid hormone promotes serine phosphorylation of p53 by mitogen-activated protein kinase,” Biochemistry, vol. 40, no. 9, pp. 2870–2878, 2001. View at Publisher · View at Google Scholar · View at Scopus
  47. A. R. D. Delbridge and A. Strasser, “The BCL-2 protein family, BH3-mimetics and cancer therapy,” Cell Death and Differentiation, vol. 22, no. 7, pp. 1071–1080, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Sun, Y. Zou, P. Wang et al., “Mitochondrial aldehyde dehydrogenase 2 plays protective roles in heart failure after myocardial infarction via suppression of the cytosolic JNK/p53 pathway in mice,” Journal of the American Heart Association, vol. 3, no. 5, Article ID e000779, 2014. View at Google Scholar · View at Scopus
  49. W.-T. Chang, J. Li, H.-H. Haung et al., “Baicalein protects against doxorubicin-induced cardiotoxicity by attenuation of mitochondrial oxidant injury and JNK activation,” Journal of Cellular Biochemistry, vol. 112, no. 10, pp. 2873–2881, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Miyashita, S. Krajewski, M. Krajewska et al., “Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo,” Oncogene, vol. 9, no. 6, pp. 1799–1805, 1994. View at Google Scholar · View at Scopus
  51. Å. B. Gustafsson and R. A. Gottlieb, “Bcl-2 family members and apoptosis, taken to heart,” American Journal of Physiology—Cell Physiology, vol. 292, no. 1, pp. C45–C51, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. V. Mikhailov, M. Mikhailova, D. J. Pulkrabek, Z. Dong, M. A. Venkatachalam, and P. Saikumar, “Bcl-2 prevents Bax oligomerization in the mitochondrial outer membrane,” The Journal of Biological Chemistry, vol. 276, no. 21, pp. 18361–18374, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. D. M. Valks, T. J. Kemp, and A. Clerk, “Regulation of Bcl-xL expression by H2O2 in cardiac myocytes,” The Journal of Biological Chemistry, vol. 278, no. 28, pp. 25542–25547, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Markou, A. A. Dowling, T. Kelly, and A. Lazou, “Regulation of Bcl-2 phosphorylation in response to oxidative stress in cardiac myocytes,” Free Radical Research, vol. 43, no. 9, pp. 809–816, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. Y.-C. Yeh, H.-C. Lai, C.-T. Ting et al., “Protection by doxycycline against doxorubicin-induced oxidative stress and apoptosis in mouse testes,” Biochemical Pharmacology, vol. 74, no. 7, pp. 969–980, 2007. View at Publisher · View at Google Scholar · View at Scopus